We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has AbbVie (ABBV - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
AbbVie is a member of our Medical group, which includes 1161 different companies and currently sits at #12 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AbbVie is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ABBV's full-year earnings has moved 1.2% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ABBV has moved about 0% on a year-to-date basis. In comparison, Medical companies have returned an average of -0.4%. This means that AbbVie is outperforming the sector as a whole this year.
Another stock in the Medical sector, Allakos Inc. (ALLK - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 0.2%.
The consensus estimate for Allakos Inc.'s current year EPS has increased 27.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, AbbVie is a member of the Large Cap Pharmaceuticals industry, which includes 14 individual companies and currently sits at #111 in the Zacks Industry Rank. On average, this group has lost an average of 0.9% so far this year, meaning that ABBV is performing better in terms of year-to-date returns.
On the other hand, Allakos Inc. belongs to the Medical - Biomedical and Genetics industry. This 538-stock industry is currently ranked #166. The industry has moved 0% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to AbbVie and Allakos Inc. as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has AbbVie (ABBV - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
AbbVie is a member of our Medical group, which includes 1161 different companies and currently sits at #12 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AbbVie is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ABBV's full-year earnings has moved 1.2% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ABBV has moved about 0% on a year-to-date basis. In comparison, Medical companies have returned an average of -0.4%. This means that AbbVie is outperforming the sector as a whole this year.
Another stock in the Medical sector, Allakos Inc. (ALLK - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 0.2%.
The consensus estimate for Allakos Inc.'s current year EPS has increased 27.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, AbbVie is a member of the Large Cap Pharmaceuticals industry, which includes 14 individual companies and currently sits at #111 in the Zacks Industry Rank. On average, this group has lost an average of 0.9% so far this year, meaning that ABBV is performing better in terms of year-to-date returns.
On the other hand, Allakos Inc. belongs to the Medical - Biomedical and Genetics industry. This 538-stock industry is currently ranked #166. The industry has moved 0% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to AbbVie and Allakos Inc. as they could maintain their solid performance.